RxDoctor Payments Data

Dhaval Patel, MD

Interventional Cardiology · Stony Brook, NYNPI 1609934256

Payments from drug & device makers

$818in general payments, 2019–2025

Across 23 payments — averaging $35.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Philips North America LLC$242
  • AbbVie$125
  • Penumbra, Inc.$89
  • Braemar Manufacturing, LLC$89
  • Alnylam Pharmaceuticals Inc.$52
  • Johnson & Johnson$39
  • plus $183 from 8 others

What the payments were for

  • Food & beverage$818100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$818 in reported general payments places this provider in the 5th percentile of 382 interventional cardiology providers in New York.

See all interventional cardiology providers in New York

Medicare billing

Part B allowed, 2024
$831,646
Medicare patients
1,199
Services billed
7,391

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban472$642,706
Repatha SyringeEvolocumab117$148,785
EntrestoSacubitril/Valsartan73$103,877
Repatha SureclickEvolocumab114$100,496
FarxigaDapagliflozin Propanediol57$74,170
Praluent PenAlirocumab111$70,225
XareltoRivaroxaban42$61,625
JardianceEmpagliflozin28$36,411
VascepaIcosapent Ethyl49$23,115
Rosuvastatin Calcium1,406$21,810
Metoprolol Succinate924$19,572
BrilintaTicagrelor22$18,918
Ezetimibe523$15,917
Atorvastatin Calcium591$7,549
Losartan Potassium497$6,169

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Brilinta$37$93,08879 claims
Johnson & JohnsonXarelto$39$61,62542 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 5th percentile of 382 interventional cardiology providers in New York.

Other interventional cardiology in Stony Brook

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →